Glenmark gets USFDA nod for Chlorpromazine HCL tablets

Glenmark has been granted a competitive generic therapy (CGT) designation for Chlorpromazine hydrochloride tablets USP

87
USFDA
Picture: Pixabay

Last Updated on March 26, 2021 by The Health Master

Glenmark Pharmaceuticals has received final approval by the United States Food and Drug Administration (USFDA) for chlorpromazine hydrochloride tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, the generic version of Thorazine1 tablets, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, of GlaxoSmithKline.

Glenmark has been granted a competitive generic therapy (CGT) designation for Chlorpromazine hydrochloride tablets USP, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg, therefore, with this approval, Glenmark is the first approved applicant for such competitive generic therapy and is eligible for 180 days of CGT exclusivity upon commercial marketing.

Medicine Tablets
Picture: Pixabay

According to IQVIATM sales data for the 12 month period ending January 2021, the Thorazine 1 tablets, 10 mg, 25 mg, 50 mg, 100 mg, and 200 mg market achieved annual sales of approximately $108.6
million.

Glenmark’s current portfolio consists of 171 products authorised for distribution in the US marketplace and 41 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Also read:

Glenmark gets USFDA nod for Diltiazem HCL ER capsules

Strides gets USFDA nod for Potassium Chloride for oral solution

Pharma Companies recall these drugs in US

AstraZeneca gets DCGI approval for Osimertinib tablets

Lupin launches generic Nitazoxanide tablets

Dr Reddy’s gets 3 observations from USFDA for US-based API plant

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner